Physicians' Attitudes Toward Pharmacogenetic Testing Before and After Pharmacogenetic Education

Overview

Journal Per Med

Specialties General Medicine
Genetics

Date 2018 May 12

PMID 29749904

Citations 21

Authors

Jasmine A Luzum

Matthew J Luzum

Affiliations

Soon will be listed here.

Abstract

Aim: Our aim was to evaluate physicians' attitudes toward pharmacogenetic testing before and after pharmacogenetic education.

Methods: In total, 12 physicians (˜40% response rate) completed a survey with eight questions on 10-point scales on their attitudes toward pharmacogenetic testing before and after a 1-h grand rounds presentation on pharmacogenetics. Differences in question scores overall, among training levels (resident/fellow/attending), and specific drugs (clopidogrel/simvastatin/warfarin) were assessed using Wilcoxon signed-rank and exact Kruskal-Wallis tests.

Results & Conclusion: The scores for all eight questions increased, with statistically significant (p < 0.05) increases for four out of eight questions. The scores were similar among training levels, but the postscores for clopidogrel were significantly higher than for simvastatin and warfarin. In conclusion, brief pharmacogenetic education can significantly affect physicians' attitudes toward pharmacogenetic testing.

Citing Articles

Assessing the knowledge, perceptions, and practices of primary care clinicians toward pharmacogenetics.

Johengen E, Ward K, Coe A, Pasternak A J Am Coll Clin Pharm. 2025; 4(1):27-32.

PMID: 39830081 PMC: 11741676. DOI: 10.1002/jac5.1341.

One Step Ahead in Realizing Pharmacogenetics in Low- and Middle-Income Countries: What Should We Do?.

Ausi Y, Barliana M, Postma M, Suwantika A J Multidiscip Healthc. 2024; 17:4863-4874.

PMID: 39464786 PMC: 11512769. DOI: 10.2147/JMDH.S458564.

It is time for educators to act: pharmacogenomics education and its implementation into clinical practice.

Kusljic S, Luzum J Pharmacogenomics. 2024; 25(10-11):425-427.

PMID: 39230518 PMC: 11492721. DOI: 10.1080/14622416.2024.2392482.

Forging the path to precision medicine in Qatar: a public health perspective on pharmacogenomics initiatives.

Bastaki K, Velayutham D, Irfan A, Adnan M, Mohammed S, Mbarek H Front Public Health. 2024; 12:1364221.

PMID: 38550311 PMC: 10977610. DOI: 10.3389/fpubh.2024.1364221.

Investigation of community pharmacists' knowledge and attitudes of pharmacogenomics testing: implication for improved pharmacogenomic testing practice.

Ramadan A, Jarab A, Al Meslamani A Hum Genomics. 2024; 18(1):8.

PMID: 38291455 PMC: 10825993. DOI: 10.1186/s40246-024-00574-z.

References

Talameh J, McLeod H, Adams Jr K, Patterson J . Genetic tailoring of pharmacotherapy in heart failure: optimize the old, while we wait for something new. J Card Fail. 2012; 18(4):338-49. DOI: 10.1016/j.cardfail.2012.01.002. View

Kimmel S, French B, Kasner S, Johnson J, Anderson J, Gage B . A pharmacogenetic versus a clinical algorithm for warfarin dosing. N Engl J Med. 2013; 369(24):2283-93. PMC: 3942158. DOI: 10.1056/NEJMoa1310669. View

Haga S, Burke W, Ginsburg G, Mills R, Agans R . Primary care physicians' knowledge of and experience with pharmacogenetic testing. Clin Genet. 2012; 82(4):388-94. PMC: 3440554. DOI: 10.1111/j.1399-0004.2012.01908.x. View

Scott S, Sangkuhl K, Stein C, Hulot J, Mega J, Roden D . Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther. 2013; 94(3):317-23. PMC: 3748366. DOI: 10.1038/clpt.2013.105. View

Relling M, Klein T . CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011; 89(3):464-7. PMC: 3098762. DOI: 10.1038/clpt.2010.279. View

Raghavan S, Vassy J . Do physicians think genomic medicine will be useful for patient care?. Per Med. 2015; 11(4):424-433. PMC: 4494677. DOI: 10.2217/pme.14.25. View

Burton A . Are we ready for direct-to-consumer genetic testing?. Lancet Neurol. 2015; 14(2):138-9. DOI: 10.1016/S1474-4422(15)70003-7. View

Ratain M, Johnson J . Meaningful use of pharmacogenetics. Clin Pharmacol Ther. 2014; 96(6):650-2. DOI: 10.1038/clpt.2014.188. View

Ramsey L, Johnson S, Caudle K, Haidar C, Voora D, Wilke R . The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther. 2014; 96(4):423-8. PMC: 4169720. DOI: 10.1038/clpt.2014.125. View

10.

Owusu-Obeng A, Weitzel K, Hatton R, Staley B, Ashton J, Cooper-DeHoff R . Emerging roles for pharmacists in clinical implementation of pharmacogenomics. Pharmacotherapy. 2014; 34(10):1102-12. PMC: 4188772. DOI: 10.1002/phar.1481. View

11.

Fargher E, Eddy C, Newman W, Qasim F, Tricker K, Elliott R . Patients' and healthcare professionals' views on pharmacogenetic testing and its future delivery in the NHS. Pharmacogenomics. 2007; 8(11):1511-9. DOI: 10.2217/14622416.8.11.1511. View

12.

Altman R . Pharmacogenomics: "noninferiority" is sufficient for initial implementation. Clin Pharmacol Ther. 2011; 89(3):348-50. DOI: 10.1038/clpt.2010.310. View

13.

Grant R, Hivert M, Pandiscio J, Florez J, Nathan D, Meigs J . The clinical application of genetic testing in type 2 diabetes: a patient and physician survey. Diabetologia. 2009; 52(11):2299-2305. PMC: 3829642. DOI: 10.1007/s00125-009-1512-7. View

14.

Johnson J, Gong L, Whirl-Carrillo M, Gage B, Scott S, Stein C . Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin Pharmacol Ther. 2011; 90(4):625-9. PMC: 3187550. DOI: 10.1038/clpt.2011.185. View

15.

Pirmohamed M, Burnside G, Eriksson N, Jorgensen A, Toh C, Nicholson T . A randomized trial of genotype-guided dosing of warfarin. N Engl J Med. 2013; 369(24):2294-303. DOI: 10.1056/NEJMoa1311386. View

16.

Zachry 3rd W, Armstrong E . Health care professionals' perceptions of the role of pharmacogenomic data. J Manag Care Pharm. 2003; 8(4):278-84. DOI: 10.18553/jmcp.2002.8.4.278. View

17.

Overby C, Erwin A, Abul-Husn N, Ellis S, Scott S, Obeng A . Physician Attitudes toward Adopting Genome-Guided Prescribing through Clinical Decision Support. J Pers Med. 2015; 4(1):35-49. PMC: 4251406. DOI: 10.3390/jpm4010035. View

18.

Gillis N, Innocenti F . Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. Clin Pharmacol Ther. 2014; 96(6):655-7. DOI: 10.1038/clpt.2014.185. View

19.

Holtzman N . Primary care physicians' perceptions of barriers to genetic testing and their willingness to participate in research. Am J Med Genet. 2000; 94(5):409-16. DOI: 10.1002/1096-8628(20001023)94:5<409::aid-ajmg13>3.0.co;2-u. View

20.

Rogausch A, Prause D, Schallenberg A, Brockmoller J, Himmel W . Patients' and physicians' perspectives on pharmacogenetic testing. Pharmacogenomics. 2005; 7(1):49-59. DOI: 10.2217/14622416.7.1.49. View